SG Americas Securities LLC acquired a new stake in GENFIT S A/ADR (NASDAQ:GNFT) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 22,816 shares of the company’s stock, valued at approximately $454,000.
Other large investors have also added to or reduced their stakes in the company. Morgan Stanley raised its stake in GENFIT S A/ADR by 24.4% in the second quarter. Morgan Stanley now owns 10,700 shares of the company’s stock valued at $211,000 after buying an additional 2,100 shares during the period. Bank of America Corp DE bought a new stake in GENFIT S A/ADR in the second quarter valued at approximately $889,000. Millennium Management LLC raised its stake in GENFIT S A/ADR by 51.4% in the third quarter. Millennium Management LLC now owns 128,001 shares of the company’s stock valued at $2,228,000 after buying an additional 43,464 shares during the period. Finally, Granahan Investment Management Inc. MA raised its stake in GENFIT S A/ADR by 4.4% in the third quarter. Granahan Investment Management Inc. MA now owns 199,695 shares of the company’s stock valued at $3,477,000 after buying an additional 8,495 shares during the period. Hedge funds and other institutional investors own 6.49% of the company’s stock.
Shares of GENFIT S A/ADR stock traded up $0.15 on Friday, hitting $18.36. The stock had a trading volume of 105 shares, compared to its average volume of 61,903. GENFIT S A/ADR has a twelve month low of $13.21 and a twelve month high of $26.25. The business’s 50 day moving average is $19.19 and its two-hundred day moving average is $16.83. The company has a debt-to-equity ratio of 1.85, a current ratio of 6.45 and a quick ratio of 6.44.
GENFIT S A/ADR Company Profile
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Featured Article: Forex
Want to see what other hedge funds are holding GNFT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GENFIT S A/ADR (NASDAQ:GNFT).
Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.